PFA

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved pulsed field ablation system

Retrieved on: 
Tuesday, April 9, 2024
Electrophysiology, St Davids, Atrial fibrillation, Arrhythmia, Patient, PFA, Medical Center, Quality of life, FDA, Food, Medical device

The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.

Key Points: 
  • The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.
  • Dr. Natale and Dr. Al-Ahmad were two of 67 global operators to participate in the trial that led to FDA approval.
  • The novel PFA system delivers short-duration, high-energy electrical pulses to the cardiac tissue to destroy cells that cause irregular heart rhythms without using excess heat or cold.
  • "Our team is honored to have played a part in piloting this new era of global innovation for cardiac arrhythmia."

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved pulsed field ablation system

Retrieved on: 
Tuesday, April 9, 2024
Electrophysiology, St Davids, Atrial fibrillation, Arrhythmia, Patient, PFA, Medical Center, Quality of life, FDA, Food, Medical device

The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.

Key Points: 
  • The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.
  • Dr. Natale and Dr. Al-Ahmad were two of 67 global operators to participate in the trial that led to FDA approval.
  • The novel PFA system delivers short-duration, high-energy electrical pulses to the cardiac tissue to destroy cells that cause irregular heart rhythms without using excess heat or cold.
  • "Our team is honored to have played a part in piloting this new era of global innovation for cardiac arrhythmia."

The Medtronic Sphere-360™ Pulse Field Ablation (PFA) catheter, a new paradigm in single-shot ablation, demonstrates impressive results in treating paroxysmal atrial fibrillation

Retrieved on: 
Monday, April 8, 2024
Freedom, Atrial fibrillation, Risk, Patient, Stroke, PFA, Medtronic, Femoral vein, Pulse, Heart failure, Ventricular fibrillation, MPH, Index, Heart, Safety, AAD, Annual general meeting, Cardiac tamponade, Pulmonary vein stenosis

DUBLIN and BERLIN, April 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical trial safety and efficacy results for Sphere-360™, an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of patients with paroxysmal atrial fibrillation (AFib). Interim findings from the first-in-human Sphere-360 study were presented as a late-breaking clinical trial at the European Heart Rhythm Association (EHRA) 2024 Annual Meeting.

Key Points: 
  • Interim findings from the first-in-human Sphere-360 study were presented as a late-breaking clinical trial at the European Heart Rhythm Association (EHRA) 2024 Annual Meeting.
  • The Sphere-360 catheter was developed with the goal to simplify the atrial fibrillation procedure while enhancing efficiency and providing high durability of lesions.
  • Furthermore, the catheter is fully integrated with the Affera™ Mapping and Ablation System for complete visualization inside the heart and electroanatomical mapping, making it a true all-in-one single-shot catheter for mapping, ablation, and validation.
  • "These results are very encouraging as they show the Sphere-360 catheter has the potential to be an important part of next generation AFib care."

Kardium Announces Completion of Paroxysmal Enrollment in the PULSAR IDE Study

Retrieved on: 
Tuesday, April 2, 2024
Software, Hardware, Medical Devices, Technology, Health Technology, Clinical Trials, Surgery, Nanotechnology, Cardiology, Biotechnology, FDA, Health, Inc., Atrial fibrillation, Patient, Gold, PFA, McGill University Health Centre, IDE, Electrode, Workflow, Heart, PMA, Safety, Patient safety, Multimedia, Mount Sinai Hospital, Food, Medical device

Kardium Inc. , a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today the successful completion of enrollment in the paroxysmal cohort of the pivotal PULSAR IDE (Investigational Device Exemption) study.

Key Points: 
  • Kardium Inc. , a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today the successful completion of enrollment in the paroxysmal cohort of the pivotal PULSAR IDE (Investigational Device Exemption) study.
  • (Photo: Business Wire)
    The PULSAR IDE study, an international, multi-center clinical trial, is designed to evaluate the safety and effectiveness of the Globe System for the treatment of atrial fibrillation.
  • The successful completion of enrollment underscores the commitment of the clinical sites, investigators, and the entire Kardium team.
  • "The completion of enrollment in the PULSAR study represents a major accomplishment for Kardium.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
Tuesday, March 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
Tuesday, March 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

Leaf Home & Nextdoor partner to reach neighbors all over the U.S. to raise awareness around the benefits of filtered water

Retrieved on: 
Tuesday, March 26, 2024
Chlorine, Taste, Learning, Trust, Microplastics, Smell, Leaf, PFA, City, Water quality, Water, Safety, Habit, Drinking water, Bottled water

NEW YORK, March 26, 2024 /PRNewswire/ -- A new study by Leaf Home™ highlights a significant disconnect between Americans' concerns about drinking water and their actual habits. The study reveals that, despite citing contaminants as their top worry, a vast majority of Americans (63%) have never had their drinking water tested. Additionally, the study found a significant rise in bottled water consumption (69%), increasing by nearly 20% since 2022. These findings also showcase a dependence on unreliable indicators of water safety, such as taste and appearance, and a lack of awareness about threats from microplastics and forever chemicals.

Key Points: 
  • A report from Leaf Home finds rising bottled water consumption, untested taps, and low public awareness of threats to drinking water.
  • "There's a surprising contrast between people's behavior, concerns, and awareness of water issues," said Jon Bostock, CEO at Leaf Home.
  • By working together, Leaf Home and Nextdoor aim to raise awareness about water quality and provide actionable solutions for healthier homes.
  • As 95% of Nextdoor neighbors are the main/joint household decision-makers, Nextdoor is the perfect place to drive awareness around Leaf Home's filtered water solutions.

Ecolectro, Green Hydrogen Startup, Successfully Achieves Breakthrough Production and Efficiency Milestones

Retrieved on: 
Tuesday, March 26, 2024
Electricity, Iridium, Cornell University, Research, History, PEM, Carbon, PFA, Chemistry, AEM, Hydrogen, Heart, Economics, Electrolysis, Renewable energy

New York-based Ecolectro's breakthrough production rates of > 4A/cm2 in their transformative anion exchange materials (AEM) electrolyzers effectively unlock attractive economics for green hydrogen production.

Key Points: 
  • New York-based Ecolectro's breakthrough production rates of > 4A/cm2 in their transformative anion exchange materials (AEM) electrolyzers effectively unlock attractive economics for green hydrogen production.
  • ITHACA, N.Y., March 26, 2024 /PRNewswire/ -- Founded on the pioneering research conducted at Cornell University, Ecolectro has developed proprietary AEM electrolyzers designed to significantly reduce the cost of green hydrogen production.
  • This breakthrough positions Ecolectro, and subsequently green hydrogen, as a viable and economically competitive energy source.
  • Ecolectro , an emerging leader in green hydrogen generation, has hit best in class performance milestones using their AEM chemistry in membrane based electrolyzers.

IDTechEx Analyzes the Potential Industry-Shifting Impact of Future PFAS Regulations in High-Tech Emerging Applications

Retrieved on: 
Monday, March 25, 2024
Immersion, Health, Membrane, Fluorine, Pressure, Development, Growth, PFAS, PFOS, Environment, Risk, Food packaging, Research, Cancer, PFOA, Human, Organization, OECD, European, PTFE, PFA, Cosmetics

In their brand new report, " Per- and Polyfluoroalkyl Substances (PFAS) 2024: Emerging Applications, Alternatives, Regulations ", IDTechEx dives deeply to explore the future trajectory of PFAS in five key emerging applications: thermal management for data centers, sustainable food packaging, electric vehicles, low-loss materials for 5G, and the hydrogen economy.

Key Points: 
  • In their brand new report, " Per- and Polyfluoroalkyl Substances (PFAS) 2024: Emerging Applications, Alternatives, Regulations ", IDTechEx dives deeply to explore the future trajectory of PFAS in five key emerging applications: thermal management for data centers, sustainable food packaging, electric vehicles, low-loss materials for 5G, and the hydrogen economy.
  • Alternatives for PFAS in emerging high-tech applications: a critical consideration
    As such, with broad legislation potentially impacting PFAS in countless different applications, it is essential for businesses to consider potential alternatives for PFAS.
  • For businesses manufacturing or using PFAS in high-tech fields, IDTechEx's new report, "Per- and Polyfluoroalkyl Substances (PFAS) 2024: Emerging Applications, Alternatives, Regulations", not only identifies the specific impact of different PFAS regulations in key emerging application areas but also identifies potential alternatives for PFAS in these areas.
  • For more information on the new IDTechEx report "Per- and Polyfluoroalkyl Substances (PFAS) 2024: Emerging Applications, Alternatives, Regulations", including downloadable sample pages, please visit www.IDTechEx.com/PFAS .

IDTechEx Analyzes the Potential Industry-Shifting Impact of Future PFAS Regulations in High-Tech Emerging Applications

Retrieved on: 
Monday, March 25, 2024
Immersion, Health, Membrane, Fluorine, Pressure, Development, Growth, PFAS, PFOS, Environment, Risk, Food packaging, Research, Cancer, PFOA, Human, Organization, OECD, European, PTFE, PFA, Cosmetics

In their brand new report, " Per- and Polyfluoroalkyl Substances (PFAS) 2024: Emerging Applications, Alternatives, Regulations ", IDTechEx dives deeply to explore the future trajectory of PFAS in five key emerging applications: thermal management for data centers, sustainable food packaging, electric vehicles, low-loss materials for 5G, and the hydrogen economy.

Key Points: 
  • In their brand new report, " Per- and Polyfluoroalkyl Substances (PFAS) 2024: Emerging Applications, Alternatives, Regulations ", IDTechEx dives deeply to explore the future trajectory of PFAS in five key emerging applications: thermal management for data centers, sustainable food packaging, electric vehicles, low-loss materials for 5G, and the hydrogen economy.
  • Alternatives for PFAS in emerging high-tech applications: a critical consideration
    As such, with broad legislation potentially impacting PFAS in countless different applications, it is essential for businesses to consider potential alternatives for PFAS.
  • For businesses manufacturing or using PFAS in high-tech fields, IDTechEx's new report, "Per- and Polyfluoroalkyl Substances (PFAS) 2024: Emerging Applications, Alternatives, Regulations", not only identifies the specific impact of different PFAS regulations in key emerging application areas but also identifies potential alternatives for PFAS in these areas.
  • For more information on the new IDTechEx report "Per- and Polyfluoroalkyl Substances (PFAS) 2024: Emerging Applications, Alternatives, Regulations", including downloadable sample pages, please visit www.IDTechEx.com/PFAS .